Genetastix Announces Research Collaboration With Hyseq
SANTA CLARA, Calif., Feb. 13 /PRNewswire/ -- Genetastix, a privately held biotechnology company and Hyseq, Inc. (Nasdaq: HYSQ - news) today announced a collaboration through which Hyseq will obtain access to Genetastix's HuMYTech(TM) technology to generate fully human monoclonal antibodies against a proprietary antigen.
Under the terms of the agreement, Genetastix will receive an upfront payment, research and development payments and Hyseq will have the option to enter into an exclusive commercial use agreement for these Genetastix antibodies. If the research program is successful, Genetastix could receive additional research and development payments, license fees, milestone payments, as well as royalties on commercial sales of the fully human antibodies developed by Genetastix.
``We are excited to enter this collaboration with Hyseq to generate fully human antibody candidates to an important clinically relevant antigen,'' stated Li Zhu, Ph.D., President and CEO of Genetastix. ``This collaboration demonstrates our ongoing efforts in offering our partners a novel approach to generating fully human antibody therapeutics.''
``Hyseq's collaboration with Genetastix will allow us to drive forward the development of antibody products based on one of our proprietary antigens,'' said Ted W. Love, M.D., President and CEO of Hyseq. ``This technology will enable us to rapidly develop antibodies against a select target up-regulated in a number of diseases.''
Genetastix is a biopharmaceutical company developing monoclonal antibody-based therapeutics to fight cancer, infectious disease, autoimmune disease and other life threatening and debilitating diseases. Genetastix has assembled HuMYTech(TM) (Human Monoclonal Antibody Yeast Technology), a unique yeast-based platform for antibody discovery and development. Genetastix's highly efficient yeast-based screening process has achieved a near 100% success rate in generating antibodies against both simple and complex antigens. Exceptionally noteworthy is Genetastix's success in producing unique antibodies to multiple epitopes of the same protein, and its efficiency in producing antibodies to the most complex membrane proteins including GPCRs (G-protein-coupled receptors), proteins with multi-trans membrane domains. The Genetastix platform is highly scalable and inexpensive to operate because it is yeast-based, and utilizes cDNA, not purified protein as antigen screening material. Genetastix creates and develops fully human antibodies for itself and others, offering a full range of antibody related discovery capabilities. For more information about Genetastix, visit its website at genetastix.com .
Hyseq Pharmaceuticals, Inc. is engaged in the research and development of biopharmaceutical products based upon its proprietary database of full-length human gene sequences. Hyseq's screening-by-hybridization platform provided a significant advantage in the discovery of novel, rarely expressed genes, and assembly of one of the most important proprietary databases of full-length human gene sequences. Hyseq is expanding and accelerating its research activities to further elucidate the role of novel genes in its proprietary database for the development and commercialization of biotherapeutic products. Information about Hyseq is available at www.hyseq.com or by phoning 408-524-8100.
SOURCE: Genetastix Corporation |
